NEW YORK (360Dx) – Chembio Diagnostics said today that it has entered a collaboration with biopharma company AstraZeneca to develop a point-of-care diagnostic test that detects an undisclosed biomarker.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.